Sort
50,496 grants matching “lung cancer”
Development of drug conjugates of R-spondin peptibodies for the treatment of colorectal cancer
$400,000Jie Cui · Wntrix, Inc. · R41 · FY2023 · CA
Rapid 3D Whole-Slide Digitization of Thick Cytopathology Slides with a Gigapixel Microscope
$400,000Mark Harfouche · Ramona Optics, Inc. · R44 · FY2020 · CA
P1 - E2F's impact on Therapeutic Efficacy
$400,000Doug Cress · H. Lee Moffitt Cancer Ctr & Res Inst · P50 · FY2012 · CA
CAREER: Leukocyte adhesion and mechanical arrest in a model capillary
$400,000David Tees · Ohio University · · FY2006 · ENG
Washington University Molecular Imaging Center
$400,000Washington University · P50 · FY2002 · CA
P4 - Lung Cancer Chemoprevention with Enzastaurin
$400,000Gerold Bepler · H. Lee Moffitt Cancer Ctr & Res Inst · P50 · FY2012 · CA
P3 - Antitumor Mechanisms of SRC Inhibitors in Lung Cancer
$400,000Eric B. Haura · H. Lee Moffitt Cancer Ctr & Res Inst · P50 · FY2012 · CA
Mechanisms and Consequences of NOTCH Dysfunction in Head and Neck Cancer
$400,000Mitchell J. Frederick · University Of Tx Md Anderson Can Ctr · R01 · FY2015 · DE
Non-invasive detection of tumor NTRK gene fusions via rapid, efficient and low-cost extracellular vesicle isolation method
$400,000Hongzhang He · Captis Diagnostics · R43 · FY2023 · CA
TARGETING IMMUNE MICROENVIRONMENT INTERACTIONS IN LUNG CANCER METASTASIS
$400,000The Trustees Of Columbia University In The City Of New York · · FY2017 · Department of the Army
Regulation and function of nonlymphoid organ CD103 dendritic cells
$400,000Stephanie S Watowich · University Of Tx Md Anderson Can Ctr · R01 · FY2019 · AI
BMX-001 as a Therapeutic Agent for Treatment of Multiple Brain Metastases.
$400,000David S. Silberstein · Biomimetix Jv, Llc · R44 · FY2021 · CA
Evaluation of lead FANA oligos targeting FOXP3, with and without anti-PD-1 mAb, as an approach for cancer immunotherapy
$400,000Veenu Aishwarya · Aum Lifetech, Inc. · R43 · FY2022 · CA
Small Molecule CUL4 Inhibitors as Dual Precision Oncology and Immuno-Oncology Drugs
$399,999Scott D Eliasof · Culnexin Therapeutics, Inc. · R41 · FY2021 · CA
Oleocanthal functional food products for breast cancer recurrence control
$399,999Khalid A El Sayed · Oleolive, Inc. · R41 · FY2020 · CA
Development and Implementation of the REmote Telehealth User-Reported caNcer Surveillance (RETURNS) Program for Lung Cancer
$399,999David D. Odell · University Of Michigan At Ann Arbor · R01 · FY2024 · HS
Policies to Inform Safe and Equitable Opioid Access for Patients with Advanced Cancer Near End of Life
$399,999Lindsay Marie Sabik · University Of Pittsburgh At Pittsburgh · R01 · FY2023 · HS
Preclinical and IND enabling studies for treatment of advanced lung cancer and other cancers metastatic to lung by pulmonary delivery of engineered Influenza A Virus (eIAV)
$399,999Mallikarjun Srivatsan · Accurius Therapeutics, Inc. · R44 · FY2023 · CA
Policies to Inform Safe and Equitable Opioid Access for Patients with Advanced Cancer Near End of Life
$399,999Lindsay Marie Sabik · University Of Pittsburgh At Pittsburgh · R01 · FY2024 · HS
Point-of-need screening device for lung cancer in low-resource settings
$399,998Nicholas Ryan Meyerson · Darwin Biosciences, Inc. · R43 · FY2025 · CA
UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER SUPPORT GRANT
$399,995Kevin J Cullen · University Of Maryland Baltimore · P30 · FY2020 · CA
PET imaging of radiation induced lung injury
$399,990Valerie Humblet · Collagen Medical, Llc · R44 · FY2020 · CA
Assessment of a Digitally Controlled Aerosolized Nicotine Replacement Therapy
$399,989James M Davis · Predictably Human, Inc. · R42 · FY2024 · DA
Development of a potent and highly brain-penetrable antimitotic agent SEAK193 to treat breast cancer brain metastasis
$399,981Wei Li · Seak Therapeutics, Llc · R41 · FY2025 · CA
Mapping Gene Networks in Colon Cancer
$399,978Norman H Lee · George Washington University · R01 · FY2009 · CA